H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 5, 2011, Pages 1017-1025

  Wei, Ning ^a   Sun, Hua ^a   Wang, Fengpeng ^b   Liu, Gengtao ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Drug resistance; H1; P glycoprotein; Reversing agents; Tetrandrine

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADENOSINE TRIPHOSPHATASE; CISPLATIN; DOXORUBICIN; GLYCOPROTEIN P; H 1; MITOGEN ACTIVATED PROTEIN KINASE 1; PACLITAXEL; RHODAMINE 123; TETRANDRINE; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ARTICLE; ASSAY; CELL LINE; CELL STRAIN KB; CELL STRAIN KBV200; CELL STRAIN MCF 7; CELL STRAIN MCF 7/ADR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UBIQUITINATION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BENZYLISOQUINOLINES; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUORESCENT DYES; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P-GLYCOPROTEIN; PHOSPHORYLATION; PROTEIN TRANSPORT; RHODAMINE 123; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 79955562995     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1397-7     Document Type: Article

References (23)

1. S Nobili I Landini B Giglioni E Mini 2006 Pharmacological strategies for overcoming multidrug resistance Curr Drug Targets 7 861 879 16842217 10.2174/138945006777709593 1:CAS:528:DC%2BD28Xms1Crsrk%3D
2. G Szakacs JK Paterson JA Ludwig C Booth-Genthe MM Gottesman 2006 Targeting multidrug resistance in cancer Nat Rev Drug Discov 5 219 234 16518375 10.1038/nrd1984 1:CAS:528:DC%2BD28XhvFOlsr8%3D (Pubitemid 43336035)
3. R Staudinger HG Knaus H Glossmann 1991 Positive heterotropic allosteric regulators of dihydropyridine binding increase the Ca2+ affinity of the L-type Ca2+ channel. Stereoselective reversal by the novel Ca2+ antagonist BM 20.1140 J Biol Chem 266 10787 10795 1645709 1:CAS:528:DyaK3MXkvVCrsb0%3D (Pubitemid 21906873)
4. L Fu Y Liang L Deng Y Ding L Chen Y Ye X Yang Q Pan 2004 Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance Cancer Chemother Pharmacol 53 349 356 14666379 10.1007/s00280-003- 0742-5 1:CAS:528:DC%2BD2cXisVWhu7Y%3D (Pubitemid 38392360)
5. LW Fu YM Zhang YJ Liang XP Yang QC Pan 2002 The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells Eur J Cancer 38 418 426 11818209 10.1016/S0959-8049(01)00356-2 1:CAS:528:DC%2BD38XovFSgsg%3D%3D (Pubitemid 34121971)
6. J Jin FP Wang H Wei G Liu 2005 Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine Cancer Chemother Pharmacol 55 179 188 15378274 10.1007/s00280-004-0868-0 1:CAS:528: DC%2BD2cXhtVGgtLzL (Pubitemid 40110061)
7. LM Chen YJ Liang X Zhang XD Su CL Dai FP Wang YY Yan LY Tao LW Fu 2009 Reversal of Pgp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue Anticancer Res 29 4597 4604 20032409 1:CAS:528:DC%2BC3cXptlekuw%3D%3D
8. XH Zhang FY Zhang XJ Ji ZY Li 1994 Vincristine-resistant human KB cell line and mechanism of multidrug resistance Yao Xue Xue Bao 29 246 251 7976338 1:CAS:528:DyaK2cXlvFGitrk%3D
9. CA Ullmann HM Eliot BK Sinha 1991 Distribution, DNA damage and cytotoxic effects of etoposide in human tumor xenografts in vivo Anticancer Res 11 1379 1382 1746894 1:CAS:528:DyaK38XpvV2ksQ%3D%3D
10. T Mosmann 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 55 63 6606682 10.1016/0022-1759(83)90303-4 1:STN:280:DyaL2c%2FovFSmtw%3D%3D (Pubitemid 14203433)
11. M Huang G Liu 1999 The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line Cancer Lett 135 97 105 10077227 10.1016/S0304-3835(98)00280-8 1:CAS:528:DyaK1MXht1Smtrc%3D
12. LS Zheng F Wang YH Li X Zhang LM Chen YJ Liang CL Dai YY Yan LY Tao YJ Mi AK Yang KK To LW Fu 2009 Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function PLoS One 4 e5172 19390592 10.1371/journal.pone.0005172
13. P Mistry AJ Stewart W Dangerfield S Okiji C Liddle D Bootle JA Plumb D Templeton P Charlton 2001 In vitro and in vivo reversal of P-glycoprotein- mediated multidrug resistance by a novel potent modulator, XR9576 Cancer Res 61 749 758 11212278 1:CAS:528:DC%2BD3MXht1Gmt78%3D (Pubitemid 32128642)
14. Z Zhang JY Wu WN Hait JM Yang 2004 Regulation of the stability of P-glycoprotein by ubiquitination Mol Pharmacol 66 395 403 15322230 10.1124/mol.104.001966 1:CAS:528:DC%2BD2cXntlCksrk%3D (Pubitemid 39329238)
15. K Katayama S Yoshioka S Tsukahara J Mitsuhashi Y Sugimoto 2007 Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein Mol Cancer Ther 6 2092 2102 17620438 10.1158/1535-7163.MCT-07- 0148 1:CAS:528:DC%2BD2sXnsV2js7g%3D (Pubitemid 47052500)
16. K Dano 1973 Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells Biochim Biophys Acta 323 466 483 4796512 10.1016/0005-2736(73)90191-0 1:CAS:528:DyaE2cXjtlKqug%3D%3D
17. S Modok HR Mellor R Callaghan 2006 Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer Curr Opin Pharmacol 6 350 354 16690355 10.1016/j.coph.2006.01.009 1:CAS:528:DC%2BD28XmslCqu7Y%3D (Pubitemid 44026037)
18. M Mimeault R Hauke SK Batra 2008 Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies Clin Pharmacol Ther 83 673 691 17786164 10.1038/sj.clpt.6100296 1:CAS:528:DC%2BD1cXkvVegsrs%3D (Pubitemid 351559599)
19. H Kim M Barroso R Samanta L Greenberger E Sztul 1997 Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells Am J Physiol 273 C687 C702 9277367 1:CAS:528:DyaK2sXlslehsbc%3D
20. JA McCubrey LS Steelman SL Abrams JT Lee F Chang FE Bertrand PM Navolanic DM Terrian RA Franklin AB D'Assoro JL Salisbury MC Mazzarino F Stivala M Libra 2006 Roles of the RAF/MEK/ERK and PI3 K/PTEN/AKT pathways in malignant transformation and drug resistance Adv Enzyme Regul 46 249 279 16854453 10.1016/j.advenzreg.2006.01.004 1:CAS:528:DC%2BD1cXhs12lurs%3D (Pubitemid 44301348)
21. JA McCubrey LS Steelman WH Chappell SL Abrams EW Wong F Chang B Lehmann DM Terrian M Milella A Tafuri F Stivala M Libra J Basecke C Evangelisti AM Martelli RA Franklin 2007 Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochim Biophys Acta 1773 1263 1284 17126425 10.1016/j.bbamcr.2006.10.001 1:CAS:528:DC%2BD2sXosFyksbk%3D (Pubitemid 47125967)
22. J Zhou M Liu R Aneja R Chandra H Lage HC Joshi 2006 Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase Cancer Res 66 445 452 16397260 10.1158/0008-5472.CAN-05-1779 1:CAS:528:DC%2BD28XhsFWlsw%3D%3D (Pubitemid 43166053)
23. M Barancik V Bohacova J Kvackajova S Hudecova O Krizanova A Breier 2001 SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance Eur J Pharm Sci 14 29 36 11457647 10.1016/S0928-0987(01)00139-7 1:CAS:528:DC%2BD3MXltF2jt7k%3D (Pubitemid 32655412)